1. Home
  2. PRPL vs IMUX Comparison

PRPL vs IMUX Comparison

Compare PRPL & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Purple Innovation Inc.

PRPL

Purple Innovation Inc.

HOLD

Current Price

$2.46

Market Cap

13.9M

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$9.46

Market Cap

155.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRPL
IMUX
Founded
2010
2016
Country
United States
United States
Employees
N/A
66
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.9M
155.8M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
PRPL
IMUX
Price
$2.46
$9.46
Analyst Decision
Hold
Strong Buy
Analyst Count
2
6
Target Price
$0.65
★ $36.00
AVG Volume (30 Days)
56.0K
★ 344.5K
Earning Date
04-28-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 152.75
38.00
EPS
N/A
★ N/A
Revenue
★ $468,725,000.00
N/A
Revenue This Year
$8.50
N/A
Revenue Next Year
$6.68
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.28
$0.51
52 Week High
$10.00
$17.43

Technical Indicators

Market Signals
Indicator
PRPL
IMUX
Relative Strength Index (RSI) 31.41 28.37
Support Level $2.30 $0.78
Resistance Level $10.00 $15.82
Average True Range (ATR) 0.31 0.71
MACD -0.01 -0.18
Stochastic Oscillator 9.75 10.41

Price Performance

Historical Comparison
PRPL
IMUX

About PRPL Purple Innovation Inc.

Purple Innovation Inc designs and manufactures sleep products. Using its GelFlex Grid technology, the company designs, manufactures, and offers branded comfort sleep products, including mattresses, pillows, cushions, mattress protectors, bases, sheets, and others. It markets and sells these products through direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: